NEUROTROPE, INC. (OTCMKTS:NTRPD) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.
(a)On December 12, 2018, Neurotrope, Inc. (the “Company”) held its 2018 annual meeting of stockholders (the “Annual Meeting”). As of October 23, 2018, the record date for the Annual Meeting, there were 7,909,693 shares of the Company’s common stock outstanding and entitled to vote. At the Annual Meeting, the holders of 4,695,248 shares of the Company’s common stock were present in person or represented by proxy, which represented 59.361% of the total shares entitled to vote at the Annual Meeting.
(b)The following actions were taken in the Annual Meeting:
| (1) | The following seven nominees were reelected to serve on the Board until the Company’s 2019 annual meeting of stockholders or until their respective successors have been elected and qualified, or until their earlier resignation or removal: |
| Name of Director Nominees | Votes For | Votes Withheld | Broker Non-Vote |
| Charles S. Ryan, J.D., Ph.D. | 2,208,931 | 55,734 | 2,430,583 |
| Joshua N. Silverman | 1,702,560 | 562,105 | 2,430,583 |
| William S. Singer | 1,721,257 | 543,408 | 2,430,583 |
| James R. Gottlieb | 2,208,931 | 55,734 | 2,430,583 |
| Shana Kay Phares | 2,208,931 | 55,734 | 2,430,583 |
| Bruce T. Bernstein | 1,721,432 | 543,233 | 2,430,583 |
| George Perry, Ph.D. | 2,208,931 | 55,734 | 2,430,583 |
| (2) | An amendment to the Neurotrope, Inc. 2017 Equity Incentive Plan, to increase the number of shares available for the grant of awards by 600,000 shares, was approved, based on the following votes: |
| Votes For | Votes Against | Votes Abstain | Broker Non-Vote |
| 1,675,464 | 582,951 | 6,250 |
2,430,583 |
| (3) | The selection of Friedman LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018, was ratified, based on the following votes: |
| Votes For | Votes Against | Votes Abstain | Broker Non-Vote |
| 4,649,490 | 43,592 | 2,166 |
| (4) | The compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement, was approved by an advisory vote, based on the following votes: |
| Votes For | Votes Against | Votes Abstain | Broker Non-Vote |
| 2,188,681 | 136,534 | 9,450 | 243,583 |
About NEUROTROPE, INC. (OTCMKTS:NTRPD)
Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer’s disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD.
